natgillin/translations-raw huggingface dataset:
Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. 
Atripla je kombinacija fiksne doze efavirenza, emtricitabina i tenofovirdizoproksilfumarata.
4 This adverse reaction was identified through post-marketing surveillance for either efavirenz, emtricitabine or tenofovir disoproxil. 
Ova je nuspojava uočena tijekom praćenja koje je nakon stavljanja u promet provedeno za efavirenz, emtricitabin ili tenofovirdizoproksil.
Itraconazole: 
itrakonazol:
2-hydroxy atorvastatin: 
2-hidroksiatorvastatin:
Dose adjustments of diltiazem when coadministered with Atripla should be guided by clinical response (refer to the Summary of Product Characteristics for diltiazem). 
Podešavanja doze diltiazema kada se primjenjuje istodobno s Atriplom treba usklađivati s kliničkim odgovorom (pogledajte sažetak opisa svojstava lijeka za diltiazem).
Emtricitabine displayed antiviral activity against HIV-1 clades A, B, C, D, E, F, and G. Tenofovir displayed antiviral activity against HIV-1 clades A, B, C, D, E, F, G, and O. Both emtricitabine and tenofovir showed strain specific activity against HIV-2 and antiviral activity against HBV. 
Tenofovir je pokazao antivirusnu aktivnost protiv skupina A, B, C, D, E, F, G i O virusa HIV-1.
Convulsions have been observed in patients receiving efavirenz, generally in the presence of a known medical history of seizures. 
U bolesnika koji primaju efavirenz uočene su konvulzije, obično uz pozitivnu anamnezu napadaja.
Raltegravir/Emtricitabine 
raltegravir/emtricitabin
Insufficient data are available to make a dosing recommendation for indinavir when dosed with Atripla. 
Nije dostupno dovoljno podataka za određivanje preporuke doze za indinavir ako se on dozira s Atriplom.
Swallow Atripla whole with water. 
Progutajte cijelu tabletu Atriple s vodom.
Integrase strand transfer inhibitor Raltegravir/Efavirenz (400 mg single dose/-) 
Inhibitor prijenosa niza integraze raltegravir/efavirenz (400 mg u jednoj dozi/-)
The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. 
Neki od mnogih čimbenika rizika za razvoj te bolesti, između ostalih, mogu biti duljina kombinirane antiretrovirusne terapije, primjena kortikosteroida, konzumiranje alkohola, teška imunosupresija, viši indeks tjelesne mase.
Rarely, pancreatitis and lactic acidosis, sometimes fatal have been reported. 
U rijetkim su slučajevima zabilježeni pankreatitis i laktacidoza, ponekad sa smrtnim ishodom.
Atripla 600 mg/200 mg/245 mg film-coated tablets Efavirenz/emtricitabine/tenofovir disoproxil 
Atripla 600 mg/200 mg/245 mg filmom obložene tablete efavirenz/emtricitabin/tenofovirdizoproksil
The mean (%CV) emtricitabine exposure increased from 12 µg•h/ml (25%) in subjects with normal renal function to 20 µg•h/ml (6%), 25 µg•h/ml (23%) and 34 µg•h/ml (6%) in patients with mild, moderate and severe renal impairment, respectively. 
Srednja je vrijednost (% koeficijenta varijacije, CV) izloženosti emtricitabinu porasla s 12 (25%) µg•h/ml u ispitanika s normalnom funkcijom bubrega na 20 (6%) µg•h/ml, 25 (23%) µg•h/ml i 34 (6%) µg•h/ml, u bolesnika s blagim, umjerenim odnosno teškim oštećenjem funkcije bubrega.
The following side effects are rare (these may affect up to 1 in every 1,000 patients): 
Sljedeće nuspojave su rijetke (mogu se pojaviti u do 1 na svakih 1000 bolesnika):
Switching from a PI-based antiretroviral regimen 
Prelazak s režima antiretrovirusne terapije na osnovi inhibitora proteaze (IP)
Atripla can reduce the amount of statins in your blood. 
Atripla može smanjiti koncentraciju statina u krvi.
The following side effects are very common (these may affect more than 1 in 10 patients) 
Sljedeće nuspojave su vrlo česte (mogu se pojaviti u više od 1 na 10 bolesnika)
If Atripla is discontinued in patients co-infected with HIV and HBV, these patients should be closely monitored for evidence of exacerbation of hepatitis (see section 4.4). 
Ako se prekine liječenje Atriplom u bolesnika koji su istodobno inficirani virusima HIV-a i HBV-a te bolesnike treba pomno nadzirati zbog pojave znakova egzacerbacije hepatitisa (vidjeti dio 4.4).
Elderly Atripla should be administered with caution to elderly patients (see section 4.4). 
Starije osobe Atripla se starijim osobama treba davati uz oprez (vidjeti dio 4.4).
Selective Serotonin Reuptake Inhibitors (SSRIs) Sertraline/Efavirenz (50 mg q.d./600 mg q.d.) 
Selektivni inhibitori ponovne pohrane serotonina (SSRI) sertralin/efavirenz (50 mg q.d./600 mg q.d.)
Co-administration of Atripla with sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is not recommended (see section 4.4). 
Primjena Atriple zajedno sa sofosbuvirom/velpatasvirom ili sofosbuvirom/velpatasvirom /voksilaprevirom se ne preporučuje (vidjeti dio 4.4).
Atripla 600 mg/200 mg/245 mg film-coated tablets 
NAZIV LIJEKA Atripla 600 mg/200 mg/245 mg filmom obložene tablete
Atripla should not be coadministered with products containing efavirenz unless needed for dose adjustment e.g. with rifampicin (see section 4.2). 
Atripla se ne smije istodobno primjenjivati s lijekovima koji sadrže efavirenz, osim kada je to potrebno zbog prilagodbe doze, npr. s rifampicinom (vidjeti dio 4.2).
Plasma concentrations and effects of warfarin or acenocoumarol are potentially increased or decreased by efavirenz. 
Efavirenz ima potencijal povećanja ili smanjenja koncentracija u plazmi i učinaka varfarina ili acenokumarola.
Diltiazem/Emtricitabine 
diltiazem/emtricitabin
Atripla (N=203) n/N (%) 
Liječena skupina Mjera ishoda Atripla (N=203) n/N (%)
Renal failure, renal impairment, elevated creatinine, hypophosphataemia and proximal tubulopathy (including Fanconi syndrome) have been reported with the use of tenofovir disoproxil in clinical practice (see section 4.8). 
Pri primjeni tenofovirdizoproksila u kliničkoj praksi, zabilježeno je zatajenje bubrega, oštećenje funkcije bubrega, povišen kreatinin, hipofosfatemija i proksimalna tubulopatija (uključujući Fanconijev sindrom) (vidjeti dio 4.8).
Norepinephrine and dopamine reuptake inhibitor Bupropion/Efavirenz [150 mg single dose (sustained release)/600 mg q.d.] 
Inhibitor ponovne pohrane norepinefrina i dopamina bupropion/efavirenz [150 mg u jednoj dozi (s održanim oslobađanjem)/600 mg q.d.]
• damage to kidney tubules 
• oštećenje bubrežnih kanalića
Hepatic impairment 
omaglica glavobolja
The administration of Atripla with food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 5.2). 
Primjenjivanje Atriple s hranom može povećati izloženost efavirenzu te može dovesti do povećane učestalosti nuspojava (vidjeti dio 4.4 i 5.2).
If a patient misses a dose of Atripla within 12 hours of the time it is usually taken, the patient should take Atripla as soon as possible and resume the normal dosing schedule. 
Ako bolesnik propusti uzeti dozu Atriple, a prošlo je manje od 12 sati od uobičajenog vremena uzimanja, bolesnik treba što prije uzeti Atriplu i potom ju nastaviti uzimati prema svom normalnom rasporedu.
Higher tenofovir concentrations could potentiate tenofovir-associated adverse events, including renal disorders. 
Više koncentracije tenofovira mogu potencirati štetne događaje povezane s tenofovirom, uključujući poremećaj rada bubrega.
There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, nelfinavir or ribavirin. 
Nema klinički značajnih farmakokinetičkih interakcija kada se tenofovirdizoproksil primjenjuje istodobno s emtricitabinom, nelfavinirom ili ribavirinom.
Vigabatrin/Tenofovir disoproxil Gabapentin/Tenofovir disoproxil 
vigabatrin/tenofovirdizoproksil gabapentin/tenofovirdizoproksil
NRTIs and NNRTIs NRTIs/Efavirenz 
Lijekovi klase NRTI i NNRTI lijekovi klase NRTI / efavirenz
Common hypertriglyceridaemia3 
Često hipertrigliceridemija3
AUC: ↓ 40% (↓ 26 to ↓ 57) Cmax: ↓ 18% (↓ 59 to ↑ 12) 
AUC: ↓ 40% (↓ 26 do ↓ 57) Cmax: ↓ 18% (↓ 59 do ↑ 12)
Efavirenz levels may increase on stopping St. John's wort. 
Razine efavirenza mogu se povećati s prestankom uzimanja gospine trave.
Use of appropriate antihistamines and/or corticosteroids is recommended when Atripla is restarted. 
U slučaju ponovne primjene Atriple preporučuje se primjena odgovarajućih antihistaminika i/ili kortikosteroida.
Efavirenz was not mutagenic or clastogenic in conventional genotoxicity assays. 
Na temelju uobičajenih analiza genotoksičnosti efavirenz nije pokazao mutageno niti klastogeno djelovanje.
Clarithromycin/Emtricitabine 
klaritromicin/emtricitabin
Concomitant use of St. John's wort is contraindicated (see section 4.3). 
Istodobna primjena gospine trave je kontraindicirana (vidjeti dio 4.3).
Norgestimate/Ethinyloestradiol/ Emtricitabine 
norgestimat/etinilestradiol/ emtricitabin
AUC12h: ↔ Cmax: ↔ 
maravirok: AUC12h: ↔ Cmax: ↔
Sertraline/Emtricitabine 
sertralin/emtricitabin
Table 3: Development of resistance in study GS-01-934 through week 144 
Tablica 3: Razvoj rezistencije u istraživanju GS-01-934 do 144. tjedna efavirenz+emtricitabin+ tenofovirdizoproksil (N=244)
Valproic acid/Emtricitabine 
valproična kiselina / emtricitabin
Atripla is not recommended for patients with moderate or severe renal impairment (creatinine clearance < 50 ml/min). 
Ne preporučuje se davanje Atriple bolesnicima s umjerenim ili teškim oštećenjem funkcije bubrega (klirens kreatinina < 50 ml/min).
Severe rash associated with blistering, moist desquamation or ulceration has been reported in less than 1% of patients treated with efavirenz (see section 4.8). 
U manje od 1% bolesnika liječenih efavirenzom zabilježen je teški oblik osipa s mjehurima, vlažna deskvamacija ili ulceracija (vidjeti dio 4.8).
For co-administration of efavirenz with low-dose ritonavir in combination with a protease inhibitor, see section on ritonavir below. 
Podatke o istodobnoj primjeni efavirenza s niskom dozom ritonavira u kombinaciji s inhibitorom proteaze potražite u odjeljku za ritonavir u nastavku.
genotype following the administration of 600 mg daily dose for 14 days was 2.25-fold the mean Cmax observed in subjects with CYP2B6 *1/*1 genotype. 
Nakon primjene dnevne doze od 600 mg tijekom 14 dana, u ispitanika s genotipom CYP2B6 *6/*6 srednja vrijednost Cmax efavirenza bila je 2,25 puta veća od srednje vrijednosti Cmax u ispitanika s genotipom CYP2B6 *1/*1.
AUC: ↓ 69% (↓ 62 to ↓ 73) Cmax: ↓ 76% (↓ 63 to ↓ 79) 
AUC: ↓ 69% (↓ 62 do ↓ 73) Cmax: ↓ 76% (↓ 63 do ↓ 79)
• dizziness, headache, diarrhoea, feeling sick (nausea), being sick (vomiting) 
• omaglica, glavobolja, proljev, mučnina, povraćanje
Uncommon hypercholesterolaemia3 
Manje često hiperkolesterolemija 3
Ethinyloestradiol+Norgestimate/Efavirenz (0.035 mg+0.25 mg q.d./600 mg q.d.) 
Peroralna primjena: etinilestradiol+norgestimat/efavire nz (0,035 mg+0,25 mg q.d./600 mg q .d.)
Patients should be monitored carefully for adverse reactions, especially nervous system symptoms related to efavirenz (see sections 4.3 and 4.4). 
Nužno je pomno pratiti dolazi li u bolesnika do razvoja nuspojava, naročito do simptoma od strane živčanog sustava povezanih s efavirenzom (vidjeti dio 4.3 i
ANTICOAGULANTS Warfarin/Efavirenz Acenocoumarol/Efavirenz 
varfarin/efavirenz acenokumarol/efavirenz
Depomedroxyprogesterone acetate (DMPA)/Efavirenz (150 mg IM single dose DMPA) 
Injekcija: depomedroksiprogesteron acetat (DMPA) / efavirenz (150 mg i.m., jedna doza DMPA)
Renal and urinary disorders: Uncommon increased creatinine, proteinuria, proximal renal tubulopathy including Fanconi syndrome 
Poremećaji bubrega i mokraćnog sustava: Manje često povišen kreatinin, proteinurija, proksimalna bubrežna tubulopatija uključujući Fanconijev sindrom
Refer to the Summary of Product Characteristics for elbasvir/grazoprevir for more information. 
Za više informacija pogledajte sažetke opisa svojstava lijeka za elbasvir/grazoprevir.
Morning AUC: ↑ 18% (↑ 6 to ↑ 33) Evening AUC: ↔ Morning Cmax: ↑ 24% (↑ 12 to ↑ 38) 
AUC ujutro: ↑ 18% (↑ 6 do ↑ 33) AUC navečer: ↔ Cmax ujutro: ↑ 24% (↑ 12 do ↑ 38) Cmax navečer: ↔
AUC: ↑ 81% (↑ 68 to ↑ 94) Cmax: ↑ 77% (↑ 53 to ↑ 104) Cmin: ↑ 121% (↑ 100 to ↑ 143) 
AUC: ↑ 81% (↑ 68 do ↑ 94) Cmax: ↑ 77% (↑ 53 do ↑ 104) Cmin: ↑ 121% (↑ 100 do ↑ 143)
Hydroxyitraconazole: 
hidroksiitrakonazol:
(competitive inhibition of oxidative metabolism) 
Cmax: ↑ 38% (kompetitivna inhibicija oksidativnog metabolizma)
AUC: ↓ 35% (↓ 13 to ↓ 40) Cmax: ↓ 13% (↓ 0 to ↓ 23) 
AUC: ↓ 35% (↓ 13 do ↓ 40) Cmax: ↓ 13% (↓ 0 do ↓ 23)
Atripla and fosamprenavir/ritonavir can be co-administered without dose adjustment. 
Atripla i fosamprenavir/ritonavir mogu se uzimati zajedno bez prilagođavanja doze.
AUC: ↔ Cmax: ↑ 38% (↑ 14 to ↑ 67) 
Cmax: ↑ 38% (↑ 14 do ↑ 67)
AUC12h: ↓ 45% (↓ 38 to ↓ 51) Cmax: ↓ 51% (↓ 37 to ↓ 62) 
AUC12h: ↓ 45% (↓ 38 do ↓ 51) Cmax: ↓ 51% (↓ 37 do ↓ 62)
Ear and labyrinth disorders: Uncommon tinnitus, vertigo 
Poremećaji uha i labirinta: Manje često tinitus, vrtoglavica
No human data on the effect of Atripla are available. 
Nema podataka o učinku Atriple na plodnost u čovjeka.
• rashes (including red spots or blotches sometimes with blistering and swelling of the skin), 
• osipi (uključujući crvene točkice ili mrlje, katkada s pojavom mjehurića i oticanjem kože), koji mogu biti alergijske reakcije
Atripla should be administered with caution to patients with mild hepatic impairment (see sections 4.3 and 4.4). 
Potrebna je pažnja u slučaju davanja Atriple bolesnicimas blagim oštećenjem funkcije jetre (vidjeti dio 4.3 i 4.4).
AUC: ↓ 4% (↓ 0 to ↓ 31) Cmax: ↓ 47% (↓ 9 to ↓ 51) 
AUC: ↓ 4% (↓ 0 do ↓ 31) Cmax: ↓ 47% (↓ 9 do ↓ 51)
LIPID LOWERING MEDICINAL PRODUCTS HMG Co-A Reductase Inhibitors Atorvastatin/Efavirenz (10 mg q.d./600 mg q.d.) 
Inhibitori HMG Co-A reduktaze atorvastatin/efavirenz (10 mg q.d./600 mg q.d.)
Insufficient data are available to make a dosing recommendation for lopinavir/ritonavir when dosed with Atripla. 
Nije dostupno dovoljno podataka za određivanje preporuke doze za lopinavir/ritonavir kada se primjenjuje s Atriplom.
Rosuvastatin/Emtricitabine 
rosuvastatin/emtricitabin
AUC: ↔ 19%* Cmax: ↔ 8% Cmin: ↓ 44% 
AUC: ↔ 19%* Cmax: ↔ 8%
No data are currently available from clinical studies with Atripla in treatment-naïve patients or in heavily pretreated patients. 
Trenutno nema dostupnih podataka iz kliničkih ispitivanja Atriple na bolesnicima koji nisu bili prethodno liječeni, kao niti na onima sa značajnim prethodnim liječenjima.
Forty-eight week data showed that high levels of virologic suppression, comparable to the original treatment regimen, were maintained in patients who were randomised to change to Atripla (see Table 4). 
Podaci za 48 tjedana pokazali su da su kod bolesnika koji su slučajnim odabirom prešli na uzimanje Atriple (vidjeti Tablicu 4) zadržane visoke razine virološke supresije, usporedive s prvotnim režimom liječenja.
Reproductive system and breast disorders: Uncommon gynaecomastia 
Poremećaji reproduktivnog sustava i dojki: Manje često ginekomastija
Co-administration of saquinavir/ritonavir and Atripla is not recommended. 
Ne preporučuje se istodobna primjena sakvinavira/ritonavira s Atriplom.
Didanosine/Efavirenz 
didanozin/efavirenz
Voriconazole: 
vorikonazol:
Co-administration with voriconazole. 
Istodobna primjena s vorikonazolom.
+ lamivudine/zidovudine group among all patients. 
+ tenofovirdizoproksil sa skupinom lamivudin/zidovudin među svim ispitanicima).
Methadone/Emtricitabine 
metadon/emtricitabin
BATCH NUMBER 
13. BROJ SERIJE Serija
- Medicines used to prevent organ transplant rejection (also called immunosuppressants), 
- Lijekovi koji se koriste za sprječavanje odbacivanja transplantiranih organa (poznati i pod nazivom imunosupresivi), kao što su ciklosporin, sirolimus ili takrolimus.
AUC: ↑ 98% (↑ 77 to ↑ 123) Cmax: ↑ 79% (↑ 56 to ↑ 104) Cmin: ↑ 163% (↑ 137 to ↑ 197) 
AUC: ↑ 98% (od ↑ 77 do ↑ 123) Cmax: ↑ 79% (od ↑ 56 do ↑ 104) Cmin: ↑ 163% (od ↑ 137 do ↑ 197)
Mild-to-moderate rash has been reported with the individual components of Atripla. 
Zabilježen je blag do umjeren osip pri uzimanju pojedinačnih komponenti Atriple.
Insufficient data are available to make a dosing recommendation for saquinavir/ritonavir when dosed with Atripla. 
Nije dostupno dovoljno podataka za određivanje preporuke doze za sakvinavir/ritonavir kada se primjenjuje s Atriplom.
AUC: ↓ 39% (↓ 30 to ↓ 46) Cmax: ↓ 26% (↓ 15 to ↓ 35) 
AUC: ↓ 39% (↓ 30 do ↓ 46) Cmax: ↓ 26% (↓ 15 do ↓ 35)
Rare lactic acidosis 
Rijetko laktacidoza
Atripla and sofosbuvir can be co-administered without dose adjustment. 
Atripla i sofosbuvir mogu se istodobno primjenjivati bez prilagodbe doziranja.
Artemether/Lumefantrine/Emtricitabine Interaction not studied. 
artemeter/lumefantrin/emtricitabin Interakcija nije ispitana. artemeter/lumefantrin/ tenofovirdizoproksil
Gilead Sciences S.r.l. 
United Kingdom Gilead Sciences Ltd.
The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil, including renal disorders. 
Povećano izlaganje tenofoviru može pojačati nuspojave povezane s tenofovirdizoproksilom, uključujući bolesti bubrega.
Methadone/Tenofovir disoproxil (40-110 mg q.d./245 mg q.d.) 
metadon/tenofovirdizoproksil (40-110 mg q.d./245 mg q.d.)
Ethinyloestradiol/Tenofovir disoproxil (-/245 mg q.d.) 
etinilestradiol/tenofovirdizoproksi l (-/245 mg q.d.)
Film-coating Iron oxide black Iron oxide red Macrogol 3350 
Film ovojnica željezov oksid, crni željezov oksid, crveni makrogol 3350 poli(vinilni alkohol) talk titanijev dioksid (E171)
AUC: ↔ Cmax: ↓ 19% (↓ 40 to ↑ 10) 
Cmax: ↓ 19% (od ↓ 40 do ↑ 10)
Ritonavir/Emtricitabine 
ritonavir/emtricitabin
Didanosine/Emtricitabine 
didanozin/emtricitabin
(induction of metabolism) 
(torsade de pointes)
You may require blood tests to check how your liver is working for 4 months after stopping treatment. 
Možda će do 4 mjeseca nakon prestanka liječenja biti potrebne krvne pretrage da bi se provjerilo kako radi Vaša jetra.
Atovaquone and proguanil hydrochloride/Efavirenz (250/100 mg single dose/600 mg q.d.) 
atovakvon i progvanil hidroklorid/efavirenz (250/100 mg u jednoj dozi/600 mg q.d.)
Rare hepatic failure3,4 
Rijetko zatajenje jetre3,4
AUC: ↓ 75% (↓ 62 to ↓ 84) Cmax: ↓ 44% (↓ 20 to ↓ 61) 
AUC: ↓ 75% (↓ 62 do ↓ 84) Cmax: ↓ 44% (↓ 20 do ↓ 61)
Tacrolimus/Emtricitabine/Tenofovir disoproxil (0.1 mg/kg q.d./200 mg/245 mg q.d.) 
takrolimus/emtricitabin/ tenofovirdizoproksil (0,1 mg/kg q.d./200 mg/245 mg q.d.)
Posaconazole/Emtricitabine 
posakonazol/emtricitabin
Lopinavir/Ritonavir: 
Atazanavir/ritonavir:
Indinavir/Emtricitabine (800 mg q8h/200 mg q.d.) 
indinavir/emtricitabin (800 mg q8h/200 mg q.d.)
AUC: ↔ Cmax: ↓ 23% (↓ 30 to ↑ 16) 
Cmax: ↓ 23% (od ↓ 30 do ↑ 16)
The following side effects are uncommon (these may affect up to 1 in every 100 patients): 
Sljedeće nuspojave su manje česte (mogu se pojaviti u do 1 na svakih 100 bolesnika):
Inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes caused death, have been reported rarely when medicines containing tenofovir disoproxil and didanosine were taken together. 
Kada su se zajedno uzimali lijekovi koji sadržavaju tenofovirdizoproksil i didanozin, u rijetkim su slučajevima zabilježene upala gušterače i laktacidoza (prekomjerna količina mliječne kiseline u krvi), koje katkada uzrokuju smrt.
Dose adjustment of warfarin or acenocoumarol may be required when co-administered with Atripla. 
Kada se varfarin ili acenokumarol primjenjuju istodobno s Atriplom, možda će biti potrebno prilagođavanje njihove doze.
Indinavir/Tenofovir disoproxil (800 mg q8h/245 mg q.d.) 
indinavir/tenofovirdizoproksil (800 mg q8h/245 mg q.d.)
Rifabutin/Emtricitabine 
rifabutin/emtricitabin
- Medicines used to treat infection with the hepatitis C virus: boceprevir, elbasvir/grazoprevir, 
- Lijekovi koji se koriste za liječenje infekcije virusom hepatitisa C: boceprevir, elbasvir/grazoprevir, simeprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voksilaprevir.
Itraconazole/Emtricitabine 
itrakonazol/emtricitabin
• liver and pancreas problems 
• poteškoće s jetrom ili gušteračom
Cmin: ↓ 12% (↓ 24 to ↑ 1) 
Cmin: ↓ 12% (↓ 24 do ↑1) (indukcija CYP3A4)
AUC: ↑ 11% (↑ 5 to ↑ 18) Cmax: ↑ 16% (↑ 6 to ↑ 26) Cmin: ↑ 13% (↑ 1 to ↑ 26) 
AUC: ↑ 11% (↑ 5 do ↑ 18) Cmax: ↑ 16% (↑ 6 do ↑ 26) Cmin: ↑ 13% (↑ 1 do ↑ 26) (indukcija CYP3A4)
Your doctor may need to consider giving you a different anticonvulsant. 
Liječnik će možda morati razmotriti primjenu drugog antikonvulziva.
See ritonavir row below. 
Pogledajte redak za ritonavir u nastavku.
Bupropion/Emtricitabine 
Bupropion/emtricitabin
CARDIOVASCULAR AGENTS Calcium Channel Blockers Diltiazem/Efavirenz (240 mg q.d./600 mg q.d.) 
Blokatori kalcijevih kanala diltiazem/efavirenz (240 mg q.d./600 mg q.d.)
- Lactic acidosis (excess lactic acid in the blood) is a rare (may affect up to 1 in every 1,000 patients) but serious side effect that can be fatal. 
na svakih 1000 bolesnika), ali ozbiljna nuspojava koja može biti smrtonosna.
CCR5 antagonist Maraviroc/Efavirenz (100 mg b.i.d./600 mg q.d.) 
Antagonist CCR5 maravirok/efavirenz (100 mg b.i.d./600 mg q.d.)
Methadone/Efavirenz (35-100 mg q.d./600 mg q.d.) 
metadon/efavirenz (35-100 mg q.d./600 mg q.d.)
AUC: ↓ 69% (↓ 55 to ↓ 79) Cmax: ↓ 60% (↓ 50 to ↓ 68) Cmin: ↓ 63% (↓ 44 to ↓ 75) 
AUC: ↓ 69% (↓ 55 do ↓ 79) Cmax: ↓ 60% (↓ 50 do ↓ 68) Cmin: ↓ 63% (↓ 44 do ↓ 75)
Simeprevir/Tenofovir disoproxil (150 mg q.d./245 mg q.d.) 
simeprevir/tenofovirdizoproksil (150 mg q.d./245 mg q.d.)
Simvastatin/Emtricitabine 
simvastatin/emtricitabin
Saquinavir/ritonavir/Efavirenz 
sakvinavir/ritonavir/efavirenz
Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in patients treated with tenofovir disoproxil and with risk factors for renal dysfunction. 
Zabilježeni su slučajevi akutnog zatajenja bubrega u bolesnika s čimbenicima rizika za poremećaj funkcije bubrega koji su liječeni tenofovirdizoproksilom nakon uvođenja visokih doza ili više nesteroidnih antiinflamatornih lijekova (NSAIL).
AUC: ↓ 37% (↓ 14 to ↓ 55) Cmax: ↓ 35% (↓ 12 to ↓ 52) Cmin: ↓ 43% (↓ 18 to ↓ 60) 
AUC: ↓ 37% (↓ 14 do ↓ 55) Cmax: ↓ 35% (↓ 12 do ↓ 52) Cmin: ↓ 43% (↓ 18 do ↓ 60)
AUC: ↓ 34% (↓ 21 to ↓ 41) Cmax: ↓ 20% (↓ 2 to ↓ 26) 
AUC: ↓ 34% (↓ 21 do ↓ 41) Cmax: ↓ 20% (↓ 2 do ↓ 26)
However, it was negative in an in vivo mouse bone marrow micronucleus assay. 
Međutim, rezultati su bili negativni u mikronukleus testu in vivo na koštanoj srži miševa.
Rifampicin/Emtricitabine 
rifampicin/emtricitabin
AUC: ↓ 55% (↓ 48 to ↓ 62) Cmax: ↓ 34% (↓ 21 to ↓ 47) 
AUC: ↓ 55% (↓ 48 do ↓ 62) Cmax: ↓ 34% (↓ 21 do ↓ 47)
Uncommon pancreatitis pancreatitis 
Manje često pankreatitis pankreatitis
AUC: ↓ 39% (↓ 27 to ↓ 50) Cmax: ↓ 29% (↓ 15 to ↓ 40) Cmin: ↓ 46% (↓ 31 to ↓ 58) 
AUC: ↓ 39% (↓ 27 do ↓ 50) Cmax: ↓ 29% (↓ 15 do ↓ 40) Cmin: ↓ 46% (↓ 31 do ↓ 58)
AUC: ↓ 27% (↓ 20 to ↓ 33) Cmax: ↓ 20% (↓ 15 to ↓ 24) Cmin: ↓ 35% (↓ 24 to ↓ 44) 
AUC: ↓ 27% (↓ 20 do ↓ 33) Cmax: ↓ 20% (↓ 15 do ↓ 24) Cmin: ↓ 35% (↓ 24 do ↓ 44)
Maraviroc/Tenofovir disoproxil (300 mg b.i.d./245 mg q.d.) 
maravirok/tenofovirdizoproksil (300 mg b.i.d./245 mg q.d.)
The pharmacokinetics of Atripla have not been studied in HIV infected patients with hepatic impairment. 
Farmakokinetika Atriple nije ispitana u bolesnika inficiranih virusom HIV-a s oštećenjem funkcije jetre.
AUC: ↓ 43% (↓ 34 to ↓ 50) Cmax: ↓ 12% (↓ 1 to ↓ 26) 
AUC: ↓ 43% (↓ 34 do ↓ 50) Cmax: ↓ 12% (↓ 1 do ↓ 26)
Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700 
Tel: + 44 (0) 8000 113 700
Atorvastatin/Emtricitabine 
atorvastatin/emtricitabin
Dihydroartemisinin (active metabolite): 
dihidroartemisinin (aktivni metabolit): AUC: ↓ 46%
Antifungals 
ANTIKONVULZIVI
Carbamazepine/Emtricitabine 
karbamazepin/emtricitabin
Difference between Atripla and original treatment regimen (95%CI) 
Razlika između Atriple i prvotnog režima liječenja (95% interval pouzdanosti[CI]) bolesnici s HIV-1 RNA < 50 kopija/ml
AUC: ↓ 38% (↓ 28 to ↓ 47) Cmax: ↓ 32% (↓ 15 to ↓ 46) Cmin: ↓ 45% (↓ 31 to ↓ 56) 
AUC: ↓ 38% (↓ 28 do ↓ 47) Cmax: ↓ 32% (↓ 15 do ↓ 46) Cmin: ↓ 45% (↓ 31 do ↓ 56)